Bicycle Therapeutics Gestion
Gestion contrôle des critères 4/4
Le PDG Bicycle Therapeutics est Kevin Lee, nommé en Sep2015, a un mandat de 9.17 ans. La rémunération annuelle totale est $ 5.54M, composée du salaire de 12.8% et des bonus 87.2%, y compris les actions et options de la société. détient directement 0.37% des actions de la société, d'une valeur de $ 5.26M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.8 ans et 5.3 ans.
Informations clés
Kevin Lee
Directeur général
US$5.5m
Rémunération totale
| Pourcentage du salaire du PDG | 12.8% |
| Durée du mandat du directeur général | 9.2yrs |
| Propriété du PDG | 0.4% |
| Durée moyenne d'occupation des postes de direction | 2.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.3yrs |
Mises à jour récentes de la gestion
Recent updates
Bicycle Therapeutics: Looking Again At An Intriguing Developmental Concern
Nov 07Bicycle Therapeutics plc (NASDAQ:BCYC) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 03
Bicycle Therapeutics (NASDAQ:BCYC) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 23Bicycle Therapeutics Is Looking Increasingly Attractive
Aug 20Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$165m |
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
Rémunération vs marché: La rémunération totale de Kevin ($USD 5.54M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.54M ).
Rémunération et revenus: La rémunération de Kevin a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Kevin Lee (56 yo)
9.2yrs
Titularisation
US$5,540,400
Compensation
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 5.3m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.4m | |
| Chief Financial Officer | 1.3yrs | US$2.88m | pas de données | |
| Chief Development Officer | 1.7yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | pas de données | pas de données | |
| Chief Operating Officer | 2.8yrs | US$5.98m | 0.024% $ 344.5k | |
| Senior VP | 1.4yrs | pas de données | 0% $ 0 | |
| Chief Technology Officer | 2.8yrs | US$3.07m | 0.073% $ 1.0m | |
| Senior Vice President of Investor Relations and Corporate Communications | no data | pas de données | pas de données | |
| Chief Legal Officer & General Counsel | 4.6yrs | pas de données | pas de données | |
| Head of Clinical and Project Management | 8.5yrs | pas de données | pas de données | |
| Senior VP of Pre-Clinical Development | 6yrs | pas de données | pas de données |
2.8yrs
Durée moyenne de l'emploi
55.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BCYC est considérée comme expérimentée (ancienneté moyenne 2.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 9.2yrs | US$5.54m | 0.37% $ 5.3m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.4m | |
| Chairman of Scientific Advisory Board | 6.5yrs | pas de données | pas de données | |
| Non-Executive Chairman | 5.7yrs | US$1.06m | 0.031% $ 441.6k | |
| Independent Non-Executive Director | 3.7yrs | US$482.29k | 0.016% $ 220.8k | |
| Independent Non-Executive Director | 5.3yrs | US$526.91k | 0.016% $ 220.8k | |
| Member of Scientific Advisory Board | 4.1yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 4.1yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 5.3yrs | US$495.41k | 0.016% $ 220.8k | |
| Member of Scientific Advisory Board | 6.5yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 4.1yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 4.1yrs | pas de données | pas de données |
5.3yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BCYC sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).